CV Lattes
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Professor at the School of Medicine of the University of São Paulo (FMUSP), Coordinator of the Discipline Planning, Implementation and Development of Randomized Clinical Trials of the Postgraduate Program of FMUSP and Senior Researcher at the Heart Institute - InCor/HCFMUSP. Reviewer and Member of the Editorial Board of several international journals, advisor to EHJ-Acute Cardiovascular Care (ACVC) and Associate Editor of the International Journal of Cardiology. Member of the Executive and/or Steering and/or NLI committees in 78 national and international multicenter studies, his area of #8203;#8203;interest covers different aspects of coronary artery disease, such as new drugs, left ventricular remodeling, coronary microcirculation, antithrombotic therapy, arrhythmias, heart failure and epidemiology. He was the founder and is the Coordinator of the ANTS Group (ANTiplatelet Therapy Study), which has among its members national and international professionals from Brazil, the USA and Europe. Among other activities, the group is currently developing a FAPESP Thematic Project on Platelet Aggregation and Antiaggregation (eight different projects), and throughout its existence has developed more than 20 Doctoral Theses completed or in different stages of development. He is a fellow of the National Council for Scientific and Technological Development (CNPq) and an active member of several Specialty Societies, such as the Brazilian Society of Cardiology (former Scientific Director, currently Representative of the State of São Paulo in the Society's Assemblies), the Cardiology Society of the State of São Paulo (former President, currently Member of the Advisory Board), the Brazilian Association of Intensive Medicine, the American Heart Association, the European Society of Cardiology (Fellow Emeritus) and the American College of Cardiology (Full Fellow), among others. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
In patients (pts) with coronary artery disease, the correlation between platelet aggregation and clinical outcomes is well established. This correlation is even more evident in high-risk pts, such as patients with diabetes and acute coronary syndromes (ACS) and/or percutaneous coronary interventions (PCI), and those with polyvascular atherosclerotic disease. The use of antiplatelet agents…
Epidemics caused by the Influenza virus are recognized for their great impact on public health. The identification of a new coronavirus strain (SARS-CoV-2) with pandemic spread has brought new challenges for diagnosis, control and therapy. The rapid and low-cost diagnosis of SARS-CoV-2 and influenza infections may allow the adoption of measures to control transmissibility both in the envi…
The recent demonstration that high on-treatment platelet reactivity is a common phenomenon, and that these patients have a worse prognosis when undergoing coronary angioplasty, along with the development of new devices for assessing platelet aggregation, reliably and relatively simple, led to an exponential increase in the scientific interest on the subject. Considering just the PubMed da…
Anticoagulation with heparin is indicated in several situations, such as acute coronary disease (in combination with antiplatelet therapy) for the prevention and treatment of venous thromboembolism and situations with high risk of thromboembolism, such as atrial fibrillation, hemodialysis and invasive procedures such as radiofrequency ablation, among others. However some studies about in…
(Only some records are available in English at this moment)
Antiplatelet therapy plays a fundamental role in preventing thromboembolic events in patients with coronary artery disease (CAD). Clopidogrel is commonly used as an antiplatelet agent. Edoxaban, a direct-acting oral anticoagulant, has demonstrated efficacy in reducing thromboembolic events in various clinical contexts. However, it remains unclear whether the addition of edoxaban to clopid…
The concurrent presence of peripheral arterial disease (PAD) and acute myocardial infarction (AMI) increases the risk of thrombotic events and worse clinical outcomes. Studies indicate that platelet aggregation is elevated in patients with PAD, which may be related to the severity of the disease. However, there are no studies that have specifically analyzed platelet aggregation in patient…
(Only some records are available in English at this moment)
There is evidence that platelets participate from the beginning of the atherosclerotic process (pre-clinical stage) to late stage of Coronary Disease, in which rupture or erosion of atherosclerotic plaque occurs, with consequent development of some form of Acute Coronary Syndromes(ACS): a) platelets may be involved in Atherosclerosis and formation of the foam cell, even in the absence of …
It is known that in comparison to clopidogrel, ticagrelor shows significant benefit regarding ischemic events and mortality. The importance of these findings, to some extent unexpected, raised the hypothesis that other properties of the medication could be partially responsible for these benefits. Recently, ticagrelor has been shown to be associated with increased adenosine plasma levels …
The association between diabetes and platelet reactivity is well known and a recent publication has shown that the recurrence of thrombotic events in the month following acute coronary syndrome treated with percutaneous coronary intervention is four times higher in the diabetic than in the non-diabetic population. The effect of oral hypoglycemic treatment on the acute phase of myocardial …
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 10 / 7 | Completed research grants |
| 4 / 4 | Ongoing scholarships in Brazil |
| 9 / 7 | Completed scholarships in Brazil |
| 24 / 19 | All research grants and scholarships |
| Associated processes | |